Ping Wen*, Sheng-Duo Chen*, Jia-Rui Wang†, Ying-He Zeng*
Oncology Research, Vol.27, No.5, pp. 583-592, 2019, DOI:10.3727/096504018X15368325811545
Abstract This study evaluated the difference in treatment response and survival profiles between drug-eluting bead
transarterial chemoembolization (DEB-TACE) and conventional transarterial chemoembolization (cTACE)
treatments in Chinese hepatocellular carcinoma (HCC) patients. A total of 120 HCC patients were consecutively enrolled in this prospective cohort study, which showed that DEB-TACE achieved higher complete
response (CR) (30.8%) compared with cTACE (7.4%) with no difference in overall response rate (ORR) for
patients treated with DEB-TACE and cTACE (80.8% vs. 73.5%). In addition, DEB-TACE was associated with
a lower rate of progressive disease (PD) compared with cTACE (1.9% vs. 11.8%). With… More >